663 related articles for article (PubMed ID: 32782018)
1. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
[TBL] [Abstract][Full Text] [Related]
2. Aquaporin-4 Autoantibodies From Neuromyelitis Optica Spectrum Disorder Patients Induce Complement-Independent Immunopathologies in Mice.
Yick LW; Ma OK; Ng RC; Kwan JS; Chan KH
Front Immunol; 2018; 9():1438. PubMed ID: 29988553
[TBL] [Abstract][Full Text] [Related]
3. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury.
Marignier R; Nicolle A; Watrin C; Touret M; Cavagna S; Varrin-Doyer M; Cavillon G; Rogemond V; Confavreux C; Honnorat J; Giraudon P
Brain; 2010 Sep; 133(9):2578-91. PubMed ID: 20688809
[TBL] [Abstract][Full Text] [Related]
4. T follicular helper cells contribute to pathophysiology in a model of neuromyelitis optica spectrum disorders.
Yick LW; Ma OK; Chan EY; Yau KX; Kwan JS; Chan KH
JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36649074
[TBL] [Abstract][Full Text] [Related]
5. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
6. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Neuromyelitis Optica Spectrum Disorders.
Chan KH; Lee CY
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445343
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
[TBL] [Abstract][Full Text] [Related]
9. Optic neuritis in neuromyelitis optica.
Levin MH; Bennett JL; Verkman AS
Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic targets for neuromyelitis optica spectrum disorder.
Tradtrantip L; Asavapanumas N; Verkman AS
Expert Opin Ther Targets; 2020 Mar; 24(3):219-229. PubMed ID: 32070155
[No Abstract] [Full Text] [Related]
11. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms.
Zhang H; Bennett JL; Verkman AS
Ann Neurol; 2011 Dec; 70(6):943-54. PubMed ID: 22069219
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
14. Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse.
Chan KH; Zhang R; Kwan JS; Guo VY; Ho PW; Ho JW; Chu AC
J Neuroimmunol; 2012 Apr; 245(1-2):32-8. PubMed ID: 22394609
[TBL] [Abstract][Full Text] [Related]
15. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
16. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
Takai Y; Misu T; Suzuki H; Takahashi T; Okada H; Tanaka S; Okita K; Sasou S; Watanabe M; Namatame C; Matsumoto Y; Ono H; Kaneko K; Nishiyama S; Kuroda H; Nakashima I; Lassmann H; Fujihara K; Itoyama Y; Aoki M
Brain; 2021 Sep; 144(8):2401-2415. PubMed ID: 33711152
[TBL] [Abstract][Full Text] [Related]
17. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica.
Tradtrantip L; Duan T; Yeaman MR; Verkman AS
J Neuroinflammation; 2019 Mar; 16(1):57. PubMed ID: 30851734
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.
Popescu BF; Guo Y; Jentoft ME; Parisi JE; Lennon VA; Pittock SJ; Weinshenker BG; Wingerchuk DM; Giannini C; Metz I; Brück W; Shuster EA; Carter J; Boyd CD; Clardy SL; Cohen BA; Lucchinetti CF
Neurology; 2015 Jan; 84(2):148-58. PubMed ID: 25503621
[TBL] [Abstract][Full Text] [Related]
19. Neuromyelitis optica pathogenesis and aquaporin 4.
Graber DJ; Levy M; Kerr D; Wade WF
J Neuroinflammation; 2008 May; 5():22. PubMed ID: 18510734
[TBL] [Abstract][Full Text] [Related]
20. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
